This company listing is no longer active
HAEK Stock Overview
Operates in the pharmaceutical sector in Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
HAEMATO AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €21.40 |
| 52 Week High | €28.00 |
| 52 Week Low | €19.80 |
| Beta | 1.29 |
| 1 Month Change | 0% |
| 3 Month Change | -1.83% |
| 1 Year Change | 8.08% |
| 3 Year Change | -25.95% |
| 5 Year Change | -56.33% |
| Change since IPO | -47.80% |
Recent News & Updates
What Is HAEMATO AG's (ETR:HAEK) Share Price Doing?
Feb 22
Potential Upside For HAEMATO AG (ETR:HAEK) Not Without Risk
Jan 04The Returns At HAEMATO (ETR:HAEK) Aren't Growing
Sep 12Recent updates
What Is HAEMATO AG's (ETR:HAEK) Share Price Doing?
Feb 22Potential Upside For HAEMATO AG (ETR:HAEK) Not Without Risk
Jan 04The Returns At HAEMATO (ETR:HAEK) Aren't Growing
Sep 12HAEMATO's (ETR:HAEK) Dividend Will Be Increased To €1.20
May 20We Like These Underlying Return On Capital Trends At HAEMATO (ETR:HAEK)
May 12HAEMATO's (ETR:HAEK) Returns On Capital Are Heading Higher
Dec 08The Strong Earnings Posted By HAEMATO (ETR:HAEK) Are A Good Indication Of The Strength Of The Business
May 24HAEMATO (ETR:HAEK) Hasn't Managed To Accelerate Its Returns
Nov 17HAEMATO (ETR:HAEK) Will Be Hoping To Turn Its Returns On Capital Around
May 30We're Not Very Worried About HAEMATO's (ETR:HAEK) Cash Burn Rate
Mar 08What Do The Returns At HAEMATO (ETR:HAEK) Mean Going Forward?
Feb 15Estimating The Fair Value Of HAEMATO AG (ETR:HAEK)
Jan 25
Is Now An Opportune Moment To Examine HAEMATO AG (ETR:HAEK)?
Jan 04Reflecting on HAEMATO's (ETR:HAEK) Share Price Returns Over The Last Three Years
Dec 14Shareholder Returns
| HAEK | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.7% | -2.0% |
| 1Y | 8.1% | 15.8% | 6.8% |
Return vs Industry: HAEK exceeded the German Healthcare industry which returned 3.4% over the past year.
Return vs Market: HAEK matched the German Market which returned 9.1% over the past year.
Price Volatility
| HAEK volatility | |
|---|---|
| HAEK Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 4.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: HAEK has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine HAEK's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 76 | Patrick Brenske | www.haemato.ag |
HAEMATO AG, together with its subsidiaries, operates in the pharmaceutical sector in Germany. It operates through Specialty Pharma and Lifestyle & Aesthetics segments. The company engages in the development, acquisition, licensing, and distribution of prescription drugs and OTC products, special cosmetics, as well as dietary supplements.
HAEMATO AG Fundamentals Summary
| HAEK fundamental statistics | |
|---|---|
| Market cap | €90.96m |
| Earnings (TTM) | €9.61m |
| Revenue (TTM) | €260.81m |
9.5x
P/E Ratio0.3x
P/S RatioIs HAEK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HAEK income statement (TTM) | |
|---|---|
| Revenue | €260.81m |
| Cost of Revenue | €241.08m |
| Gross Profit | €19.73m |
| Other Expenses | €10.12m |
| Earnings | €9.61m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.84 |
| Gross Margin | 7.56% |
| Net Profit Margin | 3.68% |
| Debt/Equity Ratio | 0.2% |
How did HAEK perform over the long term?
See historical performance and comparisonDividends
6.9%
Current Dividend Yield64%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/28 01:14 |
| End of Day Share Price | 2024/02/29 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
HAEMATO AG is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Acklin | First Berlin Equity Research GmbH |
| Cosmin Filker | GBC AG |
| Christian Ehmann | Warburg Research GmbH |